Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Study participants will receive a single dose of IMOVAX Polio™ vaccine at 2, 3, and 4 months of age, respectively. Each participant will make a total of 7 visits. Safety will be monitored at each visit and up to 30 days after each vaccination.
Age
0–0
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Subject is more than 2 months (60-89 days) old when receiving the first dose of polio vaccine.
Subject's parents/legal representative showed willingness to complete the 3 primary doses fully using IMOVAX Polio™ according to the schedule: one injection at 2, 3, 4 months old, respectively.
Informed consent form obtained from the subject's parent/legal representative.
Subject plan to live in the selected study sites for at least three months after inclusion.
You may not be if
Subject with a history of serious illness (e.g., hypersensitivity, seizure, convulsion, encephalopathy diseases)
Known or suspected impairment of immunologic function
Acute medical illness with or without fever within the last 72 hours
Subject plan to leave the study sites for at least three months after inclusion
Administration of immune globulin or other blood products within the last three months
Participation in another clinical trial at the same time
Contraindication to vaccination according to IMOVAX Polio™ leaflet.